Orthopedic Bone Cement Market

Market Overview The global orthopedic bone cement market is projected to grow from USD 819.11 million in 2025 to USD 1172.49 million by 2031, at a 6.16% compound annual growth rate. This market primarily involves polymethyl methacrylate (PMMA) grouting material used to secure prosthetic implants during joint replacement surgeries. Key growth drivers include an expanding geriatric population and the increasing prevalence of osteoarthritis, both necessitating more arthroplasty procedures. In 2025, the American Joint Replacement Registry reported an 8.8% increase in total procedural volume year-over-year, confirming rising demand. Additionally, high rates of trauma and sports injuries consistently drive the need for effective fixation solutions within healthcare systems. A significant challenge, however, is the growing preference for cementless implants, which rely on biological fixation instead of grouting agents, especially among younger patients and in North American markets, directly reducing bone cement utilization in primary procedures and intensifying competitive pressure on manufacturers. Market Driver The rising prevalence of osteoarthritis and osteoporosis is a primary determinant of the market's trajectory, significantly increasing the patient pool requiring cemented fixation. As bone density declines, surgeons increasingly depend on polymethyl methacrylate (PMMA) cement for immediate and stable implant anchorage, particularly in elderly individuals where biological or cementless integration is often compromised. This reliance is amplified by the substantial burden of skeletal fragility, necessitating frequent surgical interventions; the International Osteoporosis Foundation reported up to 37 million fragility fractures annually worldwide in individuals aged over 55 by October 2024, emphasizing the critical need for reliable fixation in fracture management and reconstructive procedures. Consequently, healthcare systems must maintain substantial inventories of bone cement. Concurrently, a surge in joint replacement and arthroplasty surgeries directly boosts product consumption, driven by expanding surgical eligibility to include younger, active patients and the clearing of procedural backlogs, which has intensified the frequency of cemented knee and hip interventions. This operational momentum is reflected in robust demand, such as Stryker's U.S. knee business growing 8.4% organically by October 2024 and Smith+Nephew's Orthopaedics unit achieving 6.0% underlying revenue growth by February 2025, confirming the sustained commercial expansion of the joint reconstruction market and associated demand for cementing agents. Market Challenge The primary impediment to market growth is the accelerating shift towards cementless implants, which utilize biological fixation rather than PMMA grouting agents. This trend fundamentally constrains the market by eliminating the necessity for bone cement in a growing proportion of joint replacement procedures. As surgeons increasingly favor press-fit implants that promote natural bone ingrowth—particularly for younger patients with superior bone quality—the total addressable volume for cementing products is significantly diminished. This preference effectively bypasses the bone cement market for primary interventions, compelling manufacturers to depend more heavily on the revision market or older demographic segments. This erosion of market share is substantiated by recent industry data; the American Joint Replacement Registry's 2024 Annual Report indicated that cementless fixation in primary total knee arthroplasties constituted approximately 22% of all procedures recorded in 2023, reflecting a continuous year-over-year increase. The steady rise of biological fixation in the knee segment, traditionally a stronghold for cemented solutions, demonstrates a direct displacement of bone cement usage, thereby limiting revenue potential and creating a long-term structural barrier for traditional bone cement suppliers. Market Trends The increasing adoption of antibiotic-loaded bone cements for infection prophylaxis represents a dominant trend, driven by healthcare providers' priority to reduce periprosthetic joint infections (PJI). Surgeons are widely standardizing the use of antimicrobial-impregnated fixatives in primary and revision arthroplasty to mitigate the substantial economic and clinical costs associated with septic failures. This prophylactic strategy is firmly established in clinical practice across major global markets, motivated by the need to protect implants from bacterial colonization immediately post-implantation. According to a May 2024 study in JAMA Network Open, an analysis of international registry data revealed that 93% of the 2.1 million primary total knee arthroplasties reviewed were performed utilizing antibiotic-loaded bone cement. Concurrently, there is a rising preference for high-viscosity cements, which offer superior handling characteristics essential for modern minimally invasive surgery (MIS) techniques. These formulations provide immediate stability and controlled application, reducing the risk of cement leakage into surrounding tissues while enabling more precise pressurization in restricted surgical fields. Manufacturers are responding by developing advanced high-viscosity products that also incorporate dual-antibiotic agents to address complex resistance profiles without compromising mechanical integrity, exemplified by Heraeus Medical's August 2024 launch of COPAL G+V bone cement, featuring a high-viscosity formulation with gentamicin and vancomycin for stable fixation and infection management. Key Market Players * Stryker Corporation * Smith & Nephew PLC * Johnson & Johnson Services, Inc. * Zimmer Biomet Holdings, Inc. * Subiton LABORATORIOS SL S.A * DJO Global Inc. * Arthrex Inc. * Tecres SpA * Synimed SARL Report Scope In this report, the Global Orthopedic Bone Cement Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Orthopedic Bone Cement Market, By Material * Polymethyl Methacrylate (PMMA) * Ceramic * Acrylic * Others # Orthopedic Bone Cement Market, By Product Type * Low Viscosity Cements * Medium Viscosity Cements * High Viscosity Cements * Antibiotic Cements # Orthopedic Bone Cement Market, By End-User * Hospitals * Orthopedic Clinics and Centers * Others # Orthopedic Bone Cement Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Orthopedic Bone Cement Market. Available Customizations: Global Orthopedic Bone Cement Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).